BioPharma & Healthcare Related News

Synlogic Meets First Discovery Milestone in Partnership with AbbVie

June 07, 2017 08:15 AM Eastern Daylight Time  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic Biotic™ leads for the treatment of [...]

By | June 7th, 2017|BioPharma & Healthcare, News, Therapeutics|

Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch (synNotch™) Receptor to Treat Cancer and Other Diseases

EMERYVILLE, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Cell Design Labs, Inc. today announced the issuance of U.S. Patent No. 9,670,281, entitled “Binding-triggered transcriptional switches and the methods of use thereof.” This patent, issued to UC San Francisco (UCSF) and [...]

By | June 7th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Digital-to-Biological Converter for On-Demand Production of Biologics Developed by Synthetic Genomics, Inc.

SAN DIEGO, May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds on-demand without any human intervention. The DBC [...]

BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics

NESS ZIONA, Israel, May 15, 2017 /PRNewswire/ -- BiomX Ltd., a leading microbiome therapeutics company, announced today that it has successfully secured $24 million in a Series A financing. The round was led by OrbiMed, Johnson & Johnson Innovation - [...]

By | May 23rd, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications

Cambridge, UK, 22 May 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Company”), the world leader in the application of gene editing technologies, today announces that it has gained exclusive worldwide rights to use a novel transposon-based technology [...]

By | May 23rd, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO

May 10, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction [...]

By | May 12th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|